reference standard comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
CA7 is a small-molecule oxytocin receptor agonist. It is said to be potent as an agonist of the oxytocin receptor and to show considerable selectivity over the vasopressin V1A receptor, where it displayed no functional activity. However, the exact affinity and activity values at these receptors do not appear to have been disclosed. The chemical synthesis of CA7 has been described. Along with its close analogue WJ0679, CA7 has the smallest chemical structure known for an oxytocin receptor agonist, with WJ0679 having about 60% of the molecular weight of LIT-001 and both WJ0679 and CA7 lacking LIT-001's tail component. Many analogues of WJ0679 and CA7 have been described. CA7 was first described in the scientific literature by a group including Michael Kassiou, Michael Bowen, Iain McGregor, and others at the University of Sydney in 2018. This group has founded a startup pharmaceutical company called Kinoxis Therapeutics and is developing small-molecule oxytocin-related drugs like KNX-100 and the KNX-200 series for potential medical use as of the 2020s.
== Safety == Hormone therapy for transgender individuals has been shown in medical literature to be generally safe, when supervised by a qualified medical professional. There are potential risks with hormone treatment that will be monitored through screenings and lab tests such as blood count (hemoglobin), kidney and liver function, blood sugar, potassium, and cholesterol. Taking more medication than directed may lead to health problems such as increased risk of cancer, heart attack from thickening of the blood, blood clots, and elevated cholesterol. Hormone therapy has been shown to improve the psychosocial well-being, and lower levels of distress among transgender individuals. Cardiovascular risks vary by hormone regimen, dose, route of administration, age, smoking status, and other individual risk factors. Estrogen therapy is associated with concern about venous thromboembolism, while testosterone therapy may affect cardiovascular risk factors such as blood pressure, lipids, weight, and erythrocytosis. A 2025 Dutch cohort study found that cardiovascular risk patterns differed between transgender women and transgender men receiving gender-affirming hormone therapy: transgender women did not have increased arterial cardiovascular risk compared with general-population men, but had increased venous thromboembolism risk, while transgender men had increased risks of myocardial infarction and ischaemic cerebrovascular accident compared with general-population women.
The government of Nicaragua cancelled visa-free travel for Cuban citizens in February 2026. This border was a frequent route to escape Cuba, used by thousands of migrants since its implementation in November 2021 following the COVID-19 pandemic and the 2021 Cuban protests. It is unclear if the measure was a direct request from United States administration but it is part of a series of concessions made by the administration of Daniel Ortega.
Sources: en.wikipedia.org
Antimicrobial peptides are produced by species across the tree of life, including: bacteria (e.g. bacteriocin, and many others) fungi (e.g. peptaibols, plectasin, and many others) cnidaria (e.g. hydramacin, aurelin) many from insects and arthropods (e.g. cecropin, attacin, melittin, mastoparan, drosomycin, thioester-containing protein 1) amphibia, frogs (magainin, dermaseptin, aurein, and others) birds (e.g. avian defensins) and mammals (e.g. cathelicidins, alpha- and beta-defensins, regIII peptides) Research has increased in recent years to develop artificially-engineered mimics of antimicrobial peptides such as SNAPPs, in part due to the prohibitive cost of producing naturally-derived AMPs. An example of this is the facially cationic peptide C18G, which was designed from the C-terminal domain of human platelet factor IV. Currently, the most widely used antimicrobial peptide is nisin; being the only FDA approved antimicrobial peptide, it is commonly used as an artificial preservative.
The iodine pit, also called the iodine hole or xenon pit, is a temporary disabling of a nuclear reactor due to the buildup of short-lived neutron poisons in the reactor core. The main isotope responsible is 135Xe, mainly produced by beta decay of 135I. 135I is a weak neutron absorber, while 135Xe is the strongest known neutron absorber. When 135Xe builds up in the fuel rods of a reactor, it significantly lowers their reactivity, by absorbing a significant amount of the neutrons that provide the nuclear reaction. The presence of 135I and 135Xe in the reactor is one of the main reasons for its power fluctuations in reaction to change of control rod positions. The buildup of short-lived fission products acting as nuclear poisons is called reactor poisoning, or xenon poisoning. The buildup of stable or long-lived neutron poisons is called reactor slagging.
Up to this point, most of AI's funding had gone to projects that used high-level symbols to represent mental objects like plans, goals, beliefs, and known facts. In the 1980s, some researchers began to doubt that this approach would be able to imitate all the processes of human cognition, especially perception, robotics, learning and pattern recognition, and began to look into "sub-symbolic" approaches. Rodney Brooks rejected "representation" in general and focussed directly on engineering machines that move and survive. Judea Pearl, Lotfi Zadeh, and others developed methods that handled incomplete and uncertain information by making reasonable guesses rather than precise logic. But the most important development was the revival of "connectionism", including neural network research, by Geoffrey Hinton and others. In 1990, Yann LeCun successfully showed that convolutional neural networks can recognise handwritten digits, the first of many successful applications of neural networks. AI gradually restored its reputation in the late 1990s and early 21st century by exploiting formal mathematical methods and by finding specific solutions to specific problems. This "narrow" and "formal" focus allowed researchers to produce verifiable results and collaborate with other fields (such as statistics, economics and mathematics). By 2000, solutions developed by AI researchers were being widely used, although in the 1990s they were rarely described as "artificial intelligence" (a tendency known as the AI effect).
=== War of the Green Lanterns === In the War of the Green Lanterns crossover, Mogo is corrupted and taken over when Krona attacks Oa with the emotional entities. Krona then uses Mogo to send out hundreds of Green Lantern rings across the universe to recruit more members to be brainwashed. Kyle Rayner and John Stewart try to stop Mogo while wielding blue and indigo rings respectively, but cannot reach him because of the Black Lantern energy that Mogo had absorbed. John uses his ring to absorb the Black Lantern energy, then destroys Mogo by firing a bullet into his core.
Sources: en.wikipedia.org
On May 5, 1961, Alan Shepard became the first American in space, launching in a ballistic trajectory on Mercury-Redstone 3, in a spacecraft he named Freedom 7. Though he did not achieve orbit like Gagarin, he was the first person to exercise manual control over his spacecraft's attitude and retro-rocket firing. After his successful return, Shepard was celebrated as a national hero, honored with parades in Washington, New York and Los Angeles, and received the NASA Distinguished Service Medal from President John F. Kennedy. American Virgil "Gus" Grissom repeated Shepard's suborbital flight in Liberty Bell 7 on July 21, 1961. Almost a year after the Soviet Union put a human into orbit, astronaut John Glenn became the first American to orbit the Earth, on February 20, 1962. His Mercury-Atlas 6 mission completed three orbits in the Friendship 7 spacecraft, and splashed down safely in the Atlantic Ocean, after a tense reentry, due to what falsely appeared from the telemetry data to be a loose heat-shield. On February 23, 1962, President Kennedy awarded Glenn with the NASA Distinguished Service Medal in a ceremony at Cape Canaveral Air Force Station. As the first American in orbit, Glenn became a national hero, and received a ticker-tape parade in New York City, reminiscent of that given for Charles Lindbergh. The United States launched three more Mercury flights after Glenn's: Aurora 7 on May 24, 1962, duplicated Glenn's three orbits, Sigma 7 on October 3, 1962, six orbits, and Faith 7 on May 15, 1963, 22 orbits (32.4 hours), the maximum capability of the spacecraft.
As of 2025, Pakistan's nominal GDP stood at US$407.79 billion, while GDP (PPP) was US$1.8 trillion in 2026. The nominal per capita GDP was US$1,700, and the GDP (PPP)/capita amounted to US$6,950 (international dollars). Around 44.7% of the population live below the international poverty line of US$4.20 a day, 16.5% live in extreme poverty on less than US$3 a day, 8% of the total labour force is unemployed, and CPI inflation in 2025 was 4.5%. Pakistan ranks near the bottom globally on the Global Gender Gap Index's economic participation and opportunity sub-index for women, reflecting very low female labour force participation and limited representation of women in senior economic roles. Pakistan's middle class is estimated to be around 40–50 million people, representing 15–20 per cent of the population. Among South Asian countries, Pakistan's GDP growth rate of 2.5% in 2024 was the second lowest after Afghanistan. Pakistan has strong potential to produce diverse food commodities due to its vast natural resource base across varied ecological and climatic zones. It has the world's 7th-largest labour force, and its diaspora of around 10 million, sent US$38.3 billion in remittances in fiscal year 2024–25, as reported by the Special Investment Facilitation Council. Pakistan's share of global exports averaged 0.14% between 1990 and 2023 and was 0.12% in 2023.
=== RNA replicons evolve rapidly === Biochemical and genetic analyses showed that the enzyme systems that replicate viral RNA molecules (reverse transcriptases and RNA replicases) lack molecular proofreading (3′ to 5′ exonuclease) activity, and that RNA sequences do not benefit from extensive repair systems analogous to those that exist for maintaining and repairing DNA sequences. Consequently, RNA genomes appear to be subject to significantly higher mutation rates than DNA genomes. For example, mutations in HIV-1 that lead to the emergence of viral mutants that are insensitive to antiviral drugs are common, and constitute a major clinical challenge.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.